Welcome to our dedicated page for Adia Nutrition news (Ticker: ADIA), a resource for investors and traders seeking the latest updates and insights on Adia Nutrition stock.
Adia Nutrition Inc. (OTCQB: ADIA) generates frequent news and updates centered on its work in regenerative medicine, stem cell therapies, and wellness-focused healthcare. Company announcements highlight developments across its Adia Med clinical platform, Adia Labs regenerative product division, and related health and wellness investments.
Recent news has focused on Adia Med of Winter Park’s Autism Spectrum Disorder (ASD) clinical study, a randomized interventional trial listed on ClinicalTrials.gov (NCT07304440). Releases describe IRB approval from BeyondBound, the study’s design comparing glutathione alone to glutathione combined with AdiaVita, and the launch of patient recruitment for approximately 100 children ages 3–12. These updates provide insight into Adia’s clinical research pipeline and its approach to combining antioxidants with umbilical cord blood-derived stem cells and exosomes.
News items also cover corporate and capital markets milestones, such as Adia’s uplisting to the OTCQB Venture Market, completion of SEC Rule 15c2‑11 requirements, and the filing of a Form 10 registration statement as a step toward full reporting status. Operational highlights include revenue growth commentary, expansion of the company’s sales infrastructure, partnerships that extend clinic oversight and marketing capabilities, and initiatives to broaden access to Adia Labs products and Adia Med services.
Additional coverage features partnerships and leadership appointments, including collaborations with media and marketing organizations and the addition of senior executives to support revenue generation and clinic network expansion. Visitors to this ADIA news page can review these releases to follow Adia Nutrition’s clinical studies, regenerative therapy offerings, clinic partnerships, and regulatory progress over time.
Adia Nutrition (OTCQB: ADIA) announced a patent-pending, randomized interventional clinical study for Autism Spectrum Disorder (NCT07304440) is now live on ClinicalTrials.gov. The trial plans to enroll approximately 100 children aged 3–12, comparing intravenous glutathione combined with umbilical cord blood-derived stem cells and exosomes (AdiaVita) versus glutathione alone.
Primary outcomes use ATEC scores to assess speech, sociability, sensory awareness, and behavior; the study includes a 24-month follow-up. Recruitment is expected to begin in January 2026 after independent IRB approval in December 2025.
Adia Nutrition (OTCQB: ADIA) recapped 2025 operational and financial milestones that management says position the company for scalable growth and a Nasdaq uplisting pathway.
Key disclosed achievements include revenue surges >200% quarter-over-quarter in preliminary Q3 results, profit margins exceeding 20%, a tripled sales force with four regional divisions, preferred-vendor access to over 4,000 personal injury physicians, divestiture of a non-core coffee subsidiary while retaining an 18% equity stake, advanced payer negotiations, and filing a Form 10 with expected approval in early 2026.
Adia Labs (OTCQB: ADIA) announced a strategic marketing partnership with BoldMD on December 17, 2025 to accelerate nationwide rollout of chiropractor-hosted pop-up longevity clinics.
The program builds on Adia Labs' alliance with Axia MD to provide physician oversight across all 50 states and aims to enable chiropractic practices to offer Adia's umbilical cord blood-derived stem cell products. BoldMD will supply targeted patient acquisition, brand development, and AI-powered CRM tools to support clinic scaling. The model targets >70,000 licensed chiropractors and cites a projected ~10% decade growth for the profession as a source pool for licensed clinic partners.
Adia Nutrition (OTCQB: ADIA) announced that independent IRB BeyondBound approved its patent-pending clinical study protocol for an Autism Spectrum Disorder (ASD) trial run by Adia Med of Winter Park LLC.
The randomized study will enroll 100 children ages 3–12 to compare combined glutathione plus umbilical cord blood-derived stem cells versus glutathione alone. Key outcomes include social interaction, communication, behavior, and quality of life.
Patient recruitment is expected to begin in January 2026. Study details have been submitted to ClinicalTrials.gov and are in final review before public posting.
Adia Nutrition (OTCQB: ADIA) filed a Form 10 registration statement with the U.S. Securities and Exchange Commission on December 8, 2025, prepared with assistance from the company's CFO, auditing accountant, corporate accountant, and legal counsel.
The filing is a strategic step toward full reporting status; once the Form 10 becomes effective (expected ~60 days after submission), Adia will begin reporting under the Securities Exchange Act of 1934 with audited financials and regular annual and quarterly disclosures. The company said Form 10 does not guarantee immediate national exchange listing such as Nasdaq and expects to announce effectiveness in early 2026. Filing materials are available on EDGAR.
Adia Med (OTCQB: ADIA) announced a media partnership with 3X physician and talk-show host Dr. Asa Andrew and The Dr. Asa Network on December 1, 2025. The agreement names Dr. Asa as an official media partner, spokesperson, and content creator for Adia Med to produce exclusive digital, social, radio, TV, podcast, and docu-series content focused on stem cell therapies and longevity medicine. Leadership states the partnership aims to increase awareness, education, and access to Adia Med's regenerative treatments and to support clinic licensing and strategic partnerships.
ADIA Nutrition (OTCQB: ADIA) submitted its complete, patent-pending regenerative protocol for pediatric Autism Spectrum Disorder to an independent Institutional Review Board on November 24, 2025 after the IRB accepted the company's initial draft and invited a final version.
The filing includes detailed methodology, safety measures, dosing regimen, and clinical endpoints and is under expert evaluation; IRB acceptance would authorize ADIA's first-ever IRB-approved human study using antioxidants and stem cells in children with ASD. The protocol remains confidential while intellectual property and clinical pathways advance; the company said a larger update will follow the IRB determination.
ADIA Nutrition (OTCQB: ADIA) will host a live webinar on Thursday, November 20, 2025 at 6:30 PM EST on Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Sclerosis and other autoimmune conditions.
Dr. Evan Thomas, MD, PhD, medical director of Adia Med HSCT Program, will discuss the science, patient outcomes, and Adia Med’s physician-led approach. Registration is available via Zoom and interested parties can contact CEO Larry Powalisz for more information or partnership inquiries.
ADIA Nutrition (OTCQB: ADIA) filed with the SEC and OTC Markets on November 17, 2025 to update its Standard Industrial Classification to 2836 (Biological Products, Except Diagnostic), replacing prior codes 2834 and 6719 to better reflect its biologics manufacturing and clinic operations.
The company noted Adia Labs sells FDA-registered 361 HCT/Ps (AdiaVita, AdiaLink) nationwide and Adia Med clinics provide regenerative treatments. The change will take effect on ADIA's next filings. ADIA also highlighted 200%+ Q3 2025 revenue growth, OTCQB uplisting progress, and an expanding clinic network.
ADIA Nutrition (OTCQB: ADIA) filed a provisional patent application with the United States Patent and Trademark Office on November 12, 2025 for a novel medical protocol aimed at enhancing regenerative outcomes.
The patent pending protocol reportedly uses unique procedural and biological mechanisms and gives ADIA a 12-month window to advance research, partnerships, and commercialization while preserving strategic confidentiality.
The company invited clinic owners and healthcare practitioners to inquire about licensing and integration of its regenerative therapies and said further updates will follow as development progresses.